A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

• Status: Completed
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The present survey was conducted to evaluate the efficacy and safety of GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison to placebo using a multicenter, double-blind, intergroup comparison method.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Japan Blood Products Organization
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria

1. Patients with primary recurrent miscarriage

2. Patients with a history of at least 4 miscarriages (not including biochemical pregnancy in the count of prior miscarriages)

3. Patients with any of the following risk factors for recurrent miscarriage

【Patients with unknown risk factors】 Patients with normal test results for each of the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype

1. Abnormal uterine morphology

2. Thyroid dysfunction

3. Chromosome abnormality in the couple

4. Positive antiphospholipid antibody

5. Factor XII deficiency

6. Protein S deficiency

7. Protein C deficiency

【Patients determined to have risk factors】 Patients with the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype despite receiving treatment for these factors

1. Abnormal uterine morphology (septate uterus): Patients who have undergone surgery

2. Thyroid dysfunction: Patients receiving medical treatment

3. Incidentally positive antiphospholipid antibody, factor XII deficiency, protein S deficiency, protein C deficiency:Patients receiving combination therapy with aspirin and heparin 4．Regardless of whether or not risk factors are present, patients should have experienced at least 1 a miscarriage of a fetus with normal chromosome karyotype 5．Patients below the age of 42 years at the time of obtaining informed consent 6．Patients who can be admitted for at least the period from the start date of administration of the study drug to the date of examination and assessment 1 week after the start of administration of the study drug 7．Patients who have given written informed consent to participate in this study

Exclusion Criteria:

1. Patients with chromosome abnormalities in themselves or their partners that are risk factors for recurrent miscarriage, patients with antiphospholipid syndrome, and patients with incidentally positive antiphospholipid antibody (when the latest test result is positive)

2. Patients in whom complications of diabetes mellitus or abnormal glucose tolerance has been identified, but who have not received appropriate treatment for this condition

3. Patients who have received intravenous immunoglobulin therapy as treatment for recurrent miscarriage in the past

4. Patients with a history of stillbirth at 22 weeks of gestation or later

5. Patients receiving treatment for malignant tumor

6. Patients with a history of thromboembolism

7. Patients with a history of shock or hypersensitivity in response to the ingredients of this drug or patients with hereditary fructose intolerance

8. Patients who have been diagnosed with IgA deficiency in the past or patients who have a serum IgA level of <5 mg/dL at laboratory tests at registration

9. Patients who have received another study drug within the period of 12 weeks prior to informed consent or who are currently participating in another clinical trial

10. Patients who are unsuitable for this study for any other reason, in the opinion of a principal investigator or sub-investigators